GeneDx Holdings (WGS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.01
- Estimate
- -$0.19
- Surprise
- +105.3%
- Revenue (period 2026-06-30)
- $114.4M
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
GeneDx Holdings (WGS) beat the -$0.19 estimate with adjusted EPS of $0.01 — a large 105.3% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates WGS Sell at 5.2/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +105.3% surprise compares with a -317.5% four-quarter average. Next scheduled report: 2026-10-27.
What argues against it
- Concentration risk — Product: diagnostic test reports
- Concentration risk — Supplier: single suppliers for laboratory instruments and materials
- Quality below floor (3.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $71.52
- Price target
- $81.34
- Stop
- $68.13
- Upside to target
- +13.7%
- Reward-to-risk
- 0.9:1
Risk check: RSI 28 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
WGS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $2.27B
- P/E (fwd)
- 63.6
- 52-week range
- $32.21–$170.87
- Off 52-week high
- 58.1%
- RSI (14)
- 28
- Volume vs avg
- 0.98×
- Score today
- 5.2/10